{"preliminary_commentary":{"by_channel":{"x_thread":28,"youtube":13,"podcast":7},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02819596\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":{"generated_at":"2026-11-01T06:37:29.388Z","note":"Automated from the 40 newest of 48 indexed sources (Feb 2023 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.","passages_read":40,"text":"- Whether MET status identifies patients who benefit from savolitinib plus durvalumab\n- Whether ctDNA can serve as a clinically useful prognostic biomarker in papillary disease\n- Whether PD-L1 or other biomarkers can guide treatment selection\n\nAlso discussed: papillary RCC treatment landscape."},"drugs_tested":[["savolitinib","durvalumab"],["durvalumab","tremelimumab"],["savolitinib"]],"indication":"metastatic clear cell and papillary renal cell carcinoma","name":"CALYPSO","nct_id":"NCT02819596","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=calypso-nct02819596. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"CALYPSO","arms":[{"description":"600 mg of Savolitinib monotherapy will administered once a day until study completion or withdrawal","label":"Savolitinib","type":"EXPERIMENTAL"},{"description":"1500 mg MEDI4736 will be administered every 4 weeks until study completion or withdrawal","label":"MEDI4736","type":"EXPERIMENTAL"},{"description":"Savolitinib and MEDI4736 will be administered at the Recommended Phase 2 dose ascertained in the phase Ib.","label":"Savolitinib and MEDI4736","type":"EXPERIMENTAL"},{"description":"Subjects will receive 75 mg of Tremelimumab and 1500 mg medi4736 every 4 weeks for the first four cycles, then 750 mg MEDI4736 every 4 weeks until study completion or withdrawal.","label":"Tremelimumab and MEDI4736","type":"EXPERIMENTAL"}],"collaborators":["Vall d'Hebron Institute of Oncology","AstraZeneca"],"completion_date":{"date":"2024-07-17","type":"ACTUAL"},"conditions":["Renal Clear Cell Carcinoma","Renal Papillary Cell Carcinoma"],"enrollment":{"count":69,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Savolitinib","otherNames":["Volitinib","AZD6094"],"type":"DRUG"},{"name":"MEDI4736","otherNames":["Durvalumab"],"type":"DRUG"},{"name":"Tremelimumab","otherNames":[],"type":"DRUG"}],"last_update":"2024-11-04","lead_sponsor":"Queen Mary University of London","official_title":"MEDI4736 Combinations in Metastatic Renal Cell Carcinoma","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2024-07-17","type":"ACTUAL"},"primary_outcomes":[{"measure":"Identify Dose Limiting Toxicity -Phase Ib","timeFrame":"6 months"},{"measure":"Overall response (OR) in patients with metastatic clear cell renal cancer","timeFrame":"18 months"},{"measure":"Overall response (OR) in patients with metastatic Papillary cell renal cancer","timeFrame":"18 months"},{"measure":"Overall response (OR)in patients with metastatic renal cell cancer -Biomarker enrichment phase","timeFrame":"11 months"}],"references":[{"citation":"Powles T et al. CALYPSO: A three-arm randomized phase II study of durvalumab alone or with savolitinib or tremelimumab in previously treated advanced clear cell renal cancer. Journal of Clinical Oncology 40, no. 17_suppl (June 10, 2022) LBA4503-LBA4503","pmid":null,"type":"RESULT"},{"citation":"Suarez C, Larkin JMG, Patel P, Valderrama BP, Rodriguez-Vida A, Glen H, Thistlethwaite F, Ralph C, Srinivasan G, Mendez-Vidal MJ, Hartmaier R, Markovets A, Prendergast A, Szabados B, Mousa K, Powles T. Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO). J Clin Oncol. 2023 May 10;41(14):2493-2502. doi: 10.1200/JCO.22.01414. Epub 2023 Feb 21.","pmid":"36809050","type":"RESULT"},{"citation":"Suarez Rodriguez et al. Overall survival results for durvalumab and savolitinib in metastatic papillary renal cancer. Journal of Clinical Oncology 2020 38:6_suppl, 619-619.","pmid":null,"type":"RESULT"},{"citation":"Suarez Rodriguez et al Clinical activity of durvalumab and savolitinib in MET-driven, metastatic papillary renal cancer. J Clin Oncol 39, 2021 (suppl 15; abstr 4511).","pmid":null,"type":"RESULT"},{"citation":"Jackson-Spence F, Larkin J, Patel P, Valderrama BP, Rodriguez-Vida A, Glen H, Thistlethwaite FC, Ralph C, Srinivasan G, Mendez-Vidal MJ, Childress M, Li W, Boyle P, Gasco A, Markovets A, Hartmaier R, Ackerman C, Szabados BE, Priyadarshini G, Jamal F, Powles T, Suarez C. CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancer. J Clin Oncol. 2026 Apr 20;44(12):1076-1082. doi: 10.1200/JCO-25-01840. Epub 2026 Mar 20.","pmid":"41861260","type":"DERIVED"}],"start_date":{"date":"2016-05-03","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"MEDI4736 Combinations in Metastatic Renal Cell Carcinoma","url":"https://clinicaltrials.gov/study/NCT02819596"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/calypso-nct02819596"}